Latest Breaking News & Top Headlines

FDA plans to approve Pfizer’s booster as early as Thursday for all adults 18 and older


BREAKING NEWS: FDA plans to approve Pfizer’s COVID-19 vaccine booster as early as Thursday for all adults 18 and older

  • FDA plans to allow Pfizer-BioNTech’s COVID-19 vaccine booster injection to all US adults as early as Thursday
  • The companies applied for an emergency authorization of their booster just a week ago
  • Pfizer’s booster is currently only approved for Americans age 65 and older, with underlying conditions or with a job that puts them at high risk

The U.S. Food and Drug Administration (FDA) plans to allow booster doses of Pfizer-BioNTech’s COVID-19 vaccine to all adults as early as Thursday, according to a report from The New York Times.

An advisory committee from the Centers for Disease Control and Prevention (CDC) plans to meet Friday to discuss data on the booster injection.

However, if both the FDA and CDC give the green light, it will be much faster than the original vaccines were approved, given that Pfizer submitted data just a week ago.

If authorization is given, the Pfizer booster will be the second authorization for all US adults behind the Johnson & Johnson booster.

The FDA plans to approve Pfizer-BioNTech’s COVID-19 vaccine booster injection for all U.S. adults as early as Thursday. Pictured: Safeway pharmacist Shahrzad Khoobyari (left) administers a Pfizer COVID-19 booster into the arm of Norman Solomon (right) in San Rafael, California, October 2021

In late August, the White House announced plans to make the additional footage available on September 20, although the plan ran into some speed bumps.

On September 17, the FDA’s independent panel of experts, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), voted 16-2 against allowing the injections.

The main concern cited by the experts was the risk of rare cases of heart inflammation for people under the age of 30 who receive the shot.

The panel did not believe that the risk of the condition was worth it for age groups that had little risk of complications from the virus anyway.

Members also expressed concerns about lowering the eligibility age to 40 or 50.

Many critics of the White House’s boostershot plan also believe the nation should instead focus on donating vaccine doses abroad, as preventing virus spread in low-income countries could prevent new variants from forming. .

A variant that develops in a country with low vaccination coverage can quickly become a problem for Americans and cause outbreaks in the state, as the Indian-born Delta variant did over the summer.

However, the committee voted unanimously to recommend Pfizer booster injections for all Americans age 65 and older, and later expanded the recommendation to include all people with serious comorbidities or in jobs that also expose them to Covid exposure.

This is a latest news item and will be updated.



Leave A Reply

Your email address will not be published.